683 Capital Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

683 Capital Management’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-60,000	Closed	-$5.46M	–	289
2023 Q1	$5.46M	Buy	+60,000	New	+$3.52M	0.41%	67

Other funds holding RETA

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

683 Capital Management's RETA Position: Q2 2023 in Review

683 Capital Management sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q2 2023, closing a stake of 60,000 shares — an estimated $5.46M sold.

683 Capital Management first reported a position in RETA in Q1 2023 and held it in 1 quarter. The position peaked at $5.46M in Q1 2023. 214 funds tracked by Wall St. Rank hold RETA as of Q2 2023.

683 Capital Management reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q2 2023 after selling out during the quarter.
683 Capital Management sold 60,000 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q2 2023, an estimated $5.46M.
683 Capital Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2023 and held it in 1 quarter.
683 Capital Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $5.46M in Q1 2023.
214 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q2 2023.

Based on 683 Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.